GHRP-6 10mg vial

NOT FOR HUMAN CONSUMPTION

GHRP-6 is a hexapeptide ghrelin/secretagogue receptor (GHSR-1a) agonist that triggers pulsatile growth-hormone (GH) release from pituitary somatotrophs via Gq/PLC/IP₃–Ca²⁺ signalling. It synergizes with GHRH (e.g., sermorelin/CJC) and is partly antagonized by somatostatin. Centrally, it activates NPY/AgRP circuits → orexigenic appetite and GI effects. Downstream GH elevates IGF-1, supporting anabolism, connective-tissue turnover, and recovery. GHRP-6 is not FDA/EMA-approved; it is a research peptide and prohibited by WADA (S2: GH-releasing substances).

Additional Benefits of GHRP-6 Now Under Investigation

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

• Primary target: GHSR-1a (ghrelin receptor) on hypothalamic neurons and pituitary somatotrophs → Gq/PLC → IP₃/Ca²⁺ → GH exocytosis.

• Axis biology: Synergizes with GHRH; blunted by somatostatin; preserves physiologic pulsatility versus continuous GH.

• Central effects: Activates NPY/AgRP (orexigeny), modulates sleep circuits, and affects autonomic tone.

2.2 Down-stream Biology

3. Pharmacokinetics

• Route: SC (research/clinical physiology).

• Onset/peak: GH peaks ~20–45 min post-dose; returns to baseline by ~2–3 h.

• Half-life: Short (≈15–30 min) for peptide; biological effects exceed plasma residence.

• Dosing in studies: ~1–2 µg/kg SC per pulse; common research use 100–200 µg 1–3×/day. Co-administration with GHRH analogs (e.g., CJC-1295-no-DAC/sermorelin) potentiates GH/IGF-1.

4. Pre-clinical and Translational Evidence

4.1 GH Axis & Body Composition

Repeated dosing elevates IGF-1 and fat-free mass signals; fat-mass effects depend on dietary intake (orexigeny can offset lipolysis without nutrition control).

4.2 Musculoskeletal/Repair

Animal and human physiology show collagen synthesis up-regulation and improved tendon matrix organisation with GH/IGF-1 signalling; targeted trials with GHRP-6 are still limited.

4.3 Cardiometabolic

Ghrelin-mimetic actions may improve endothelial function and LV performance in HF/ischemia models; confirmatory human data for GHRP-6 specifically are pending.

Evidence quality note: Strong physiology and class-level data for GH pulsatility and orexigeny; specific randomized human outcomes with GHRP-6 are limited. Extrapolate with caution.

5. Emerging Clinical Interests

6. Safety and Tolerability

• Common: Marked hunger, flushing/warmth, transient lightheadedness, peripheral edema, carpal-tunnel-like paresthesias, headache, injection-site irritation, reflux/heartburn.

• Endocrine: Prolactin and cortisol can rise acutely; IGF-1 elevation depends on frequency/co-therapy.

• Metabolic: Ghrelin-like signalling may raise fasting glucose/insulin; manage diet and monitor in prediabetes/diabetes.

• CV/Renal: Sodium/water retention → BP drift in susceptible patients.

• Neuropsych: Vivid dreams/insomnia in a minority (timing dependent).

• Contraindications/Caution: Active malignancy, proliferative retinopathy, uncontrolled diabetes, severe OSA, pregnancy.

• Drug interactions: Additive effects with other GH secretagogues; theoretical interactions with dopamine/prolactin modulators and acid-suppressants (for reflux).

Comparative safety matrix

7. Regulatory Landscape

• Approvals: None for any indication.

• Sport: WADA-prohibited (S2, GH-releasing substances).

• Supply quality: Research-chemical products vary; ensure GMP-grade material in any formal study.

8. Future Directions

• Chronopharmacology: Optimize bedtime vs pre-training pulses for SWS and recovery while managing reflux.

• Combination therapy: Pair GHRP-6 + GHRH analogs to lower dose burden and enhance physiologic pulsatility; consider GLP-1/GIP co-therapy to temper orexigeny in weight-sensitive populations.

• Indication-focused trials: Sarcopenia/rehab (DXA, stair-climb power), tendon healing (MRI/US elastography), bone (DXA + turnover markers), HFpEF/HFrEF physiology (VO₂, endothelial function).

• Safety program: Glycaemic outcomes, BP/edema, PRL/Cort monitoring, and sleep metrics; standardized reflux mitigation.

• Formulation science: Stabilized or depot analogs for consistent, lower-dose pulsatility with fewer GI effects.

Selected References

• Journal of Clinical Endocrinology & Metabolism; Endocrine Reviews, Human GH secretagogue physiology, GHRP-class pharmacology.

• Sleep; Psychoneuroendocrinology, GH–sleep coupling and SWS effects.

• American Journal of Sports Medicine; Journal of Orthopaedic Research, Collagen synthesis and tendon/ligament repair biology under GH/IGF-1.

• Bone; Journal of Bone and Mineral Research, Bone-formation markers and GH/IGF-1 effects.

• Circulation; Cardiovascular Research, Ghrelin-pathway cardiovascular actions (endothelial/LV effects).

• Gastroenterology; Gut, GI motility and mucosal protection with ghrelin mimetics.

• Clinical Nutrition; Supportive Care in Cancer, Appetite/weight and functional recovery in catabolic states.

• Sports Medicine; Journal of Physiology, Training synergy with anabolic endocrine support.

• Drug Testing & Analysis; WADA Prohibited List, Anti-doping status and detection considerations.